Tags

Type your tag names separated by a space and hit enter

Role of genetics in the prediction of statin-associated muscle symptoms and optimization of statin use and adherence.
Cardiovasc Res. 2018 07 01; 114(8):1073-1081.CR

Abstract

Statin therapy reduces cardiovascular events in patients with, or at risk of, atherosclerotic cardiovascular disease. However, statins are underutilized in patients for whom they are indicated and are frequently discontinued. Discontinuation may be the result of statin-associated muscle symptoms (SAMS), which encompass a broad spectrum of clinical phenotypes from myalgia to severe myopathy. As with many adverse drug reactions (ADRs), inter-individual variability in susceptibility to SAMS is due, at least in part, to differences in host genetics. The genetic basis for SAMS has been investigated in candidate gene studies, genome-wide association studies, and, more recently, studies of multi-omic networks, including at the transcriptome level. In this article, we provide a systematic review of the pharmacogenetic basis of SAMS, focusing on how an understanding of the genetic and molecular determinants of SAMS can be considered in a personalized approach to reduce the incidence of this ADR, optimize statin adherence, and reduce the risk for cardiovascular events.

Authors+Show Affiliations

Department of Medicine, Centre for Heart Lung Innovation, University of British Columbia, St. Paul's Hospital, Rm 166 - 1081 Burrard St., Vancouver, British Columbia V6Z 1Y6, Canada. Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.Department of Medicine, Neuromuscular Disease Clinic, McMaster University, Hamilton, Ontario, Canada.Muscle Disease Unit, National Institutes of Health, Bethesda, MD, USA.Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Systematic Review

Language

eng

PubMed ID

29878063

Citation

Brunham, Liam R., et al. "Role of Genetics in the Prediction of Statin-associated Muscle Symptoms and Optimization of Statin Use and Adherence." Cardiovascular Research, vol. 114, no. 8, 2018, pp. 1073-1081.
Brunham LR, Baker S, Mammen A, et al. Role of genetics in the prediction of statin-associated muscle symptoms and optimization of statin use and adherence. Cardiovasc Res. 2018;114(8):1073-1081.
Brunham, L. R., Baker, S., Mammen, A., Mancini, G. B. J., & Rosenson, R. S. (2018). Role of genetics in the prediction of statin-associated muscle symptoms and optimization of statin use and adherence. Cardiovascular Research, 114(8), 1073-1081. https://doi.org/10.1093/cvr/cvy119
Brunham LR, et al. Role of Genetics in the Prediction of Statin-associated Muscle Symptoms and Optimization of Statin Use and Adherence. Cardiovasc Res. 2018 07 1;114(8):1073-1081. PubMed PMID: 29878063.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Role of genetics in the prediction of statin-associated muscle symptoms and optimization of statin use and adherence. AU - Brunham,Liam R, AU - Baker,Steven, AU - Mammen,Andrew, AU - Mancini,G B John, AU - Rosenson,Robert S, PY - 2018/01/25/received PY - 2018/05/31/accepted PY - 2018/6/8/pubmed PY - 2019/8/14/medline PY - 2018/6/8/entrez SP - 1073 EP - 1081 JF - Cardiovascular research JO - Cardiovasc. Res. VL - 114 IS - 8 N2 - Statin therapy reduces cardiovascular events in patients with, or at risk of, atherosclerotic cardiovascular disease. However, statins are underutilized in patients for whom they are indicated and are frequently discontinued. Discontinuation may be the result of statin-associated muscle symptoms (SAMS), which encompass a broad spectrum of clinical phenotypes from myalgia to severe myopathy. As with many adverse drug reactions (ADRs), inter-individual variability in susceptibility to SAMS is due, at least in part, to differences in host genetics. The genetic basis for SAMS has been investigated in candidate gene studies, genome-wide association studies, and, more recently, studies of multi-omic networks, including at the transcriptome level. In this article, we provide a systematic review of the pharmacogenetic basis of SAMS, focusing on how an understanding of the genetic and molecular determinants of SAMS can be considered in a personalized approach to reduce the incidence of this ADR, optimize statin adherence, and reduce the risk for cardiovascular events. SN - 1755-3245 UR - https://www.unboundmedicine.com/medline/citation/29878063/Role_of_genetics_in_the_prediction_of_statin_associated_muscle_symptoms_and_optimization_of_statin_use_and_adherence_ L2 - https://academic.oup.com/cardiovascres/article-lookup/doi/10.1093/cvr/cvy119 DB - PRIME DP - Unbound Medicine ER -